Tigilanol tiglate

Drug Profile

Tigilanol tiglate

Alternative Names: EBC-46

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QBiotics
  • Class Antineoplastics; Diterpenes; Esters; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Jun 2017 QBiotics completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia, New Zealand (Intratumoural) (ACTRN12614000685617)
  • 14 Jun 2017 Qbiotics completes a phase I extension trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (ACTRN12614001207606)
  • 11 May 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top